All In Biotech

Drug Trial Radar · NCT06764238

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Jan 3, 2025

Primary completion

Dec 31, 2029

Study completion Jun 2031

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I/HR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore: 1. The efficacy of two randomized Blinatumomab application scheme on I/HR-ALL as determined by MRD negatvitiy rate. 2. The efficacy of modified mini-hyperCVD + Venetoclax in I/HR-ALL cannot afford blinatumomab, in contrast to historical control as determined by MRD negatvitiy rate.

Conditions

  • Acute Lymphoblastic Leukemia ALL
  • Childhood Leukemia, Acute Lymphoblastic
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • Blinatumomab (Group A)Drug

    For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy

  • Venetoclax (nonRand Group)Drug

    For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy

  • Blinatumomab (Group B)Drug

    For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate if Group B[2*(14-day blinatumomab + HDMTX*2)] can result in noninferior event-free survival (EFS) compared to Group A [28-day blinatumomab + HDMTX*4Time frame: Based on the above analysis in this study the investigators will randomize 1800 patients. The analysis will start1.5 years after the last patient is randomized. The expected study duration is approximately 6.5 years.

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Chongqing Medical University Affiliated Children's Hospital

    Chongqing, China · Not yet recruiting

  • Children's Hospital of Fudan University

    Shanghai, China · Not yet recruiting

  • Shanghai Children's Hospital

    Shanghai, China · Not yet recruiting

  • Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Not yet recruiting

  • Anhui Medical University Second Affiliated Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Children's Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Wuhan Children's Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Children's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of the Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Nanjing Children's Hospital Affiliated to Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Xi'an Northwest Women and Children Hospital

    Xi’an, Shanxi, China · Not yet recruiting

  • Shenzhen Children's Hospital

    Shenzhen, Shenzhen, China · Not yet recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

    Tianjin, Tianjin Municipality, China · Recruiting

  • Hong Kong Children's Hospital

    Hong Kong, Hong Kong · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.